Kornimate/medical-research-clean huggingface dataset:
increase protein intake in elderly

Conditions: Markedly Reduced Food Intake

Summary: the objective of this study is to investigate the acceptance, intake, and compliance of protein enriched bread and protein enriched yoghurt drinks in elderly patients in two real life settings (short term; hospital, and longer term; rehabilitation home).

prevalence rates of protein-energy malnutrition in elderly are high. in order to prevent loss of muscle mass and remain physically independent, it is utmost important for elderly to maintain their body protein mass. a sufficient protein supply according to their needs is therefore highly important. especially for frail elderly, it is not easy to realize an increased protein intake by simply eating more. it is hypothesized that protein enriched food products that fit in a habitual diet (dairy and bread), result in a higher protein intake compared to regular products.

Eligibility criteria:
inclusion criteria: * admitted to the department of internal medicine of vu university medical center or to the rehabilitation department of "herstelhotel dekkerswald" * signed informed consent * age of 55 or more * rehabilitating from a hospital stay with the aim to return back home (rehabilitation home only) * likely to remain admitted at least 3 weeks (rehabilitation home only). exclusion criteria: * not speaking dutch language * allergy for milk, soy or gluten * a medical condition that is considered by the treating physician as a contra indication for receiving protein enriched food products * a diet that does not allow the use of normal bread or dairy products (e.g. fluid diet, strong sodium restricted diet) * not able to eat or feed themselves * receiving tube feeding or parenteral nutrition * suffering from a terminal illness

Keywords: malnutrition undernourishment loss of muscle mass
post cardiac surgery neurocognitive decline: correlations between neuropsychological tests and functional mri techniques

Conditions: Postoperative Cognitive Dysfunction

Summary: postoperative cognitive decline (pocd) is a frequent complication after cardiac surgery. it is estimated that 40-70% of all cardiac patients show cognitive dysfunction during the first post-surgical week. six weeks after surgery, this incidence decreases to 10-40% and the figure remains stable over the long-term. the investigators will recruit 50 patients undergoing elective valve surgery and each patient will receive complete evaluation a) preoperative, one week before surgery; b) early postoperative, before hospital discharge; and c) late postoperative, 8 weeks follow up. the investigators will apply diffusion tensor imaging, 1proton-magnetic resonance spectroscopy and morphometry studies with correlation to neuropsychological test battery to evaluate pocd.


Eligibility criteria:
inclusion criteria: * patients undergoing elective valve surgery in ospedale del cuore, fondazione g. monasterio, massa, italy will prospectively enter the study. exclusion criteria: * history of head trauma, seizures, stroke, carotid artery stenosis (\>70%) * history of any major surgery with general anesthesia * preoperative mmse score less than 23 to exclude patients with dementia and mild cognitive impairment (mci) * subjects who will be unable to complete the baseline neuropsychological battery due to cognitive impairment, psychiatric disease, substance abuse, blindness, or poor knowledge of italian language * any major neurological complication after cabg surgery (stroke, seizures, encephalopathy not resolving within few postoperative days) * if any contraindications to mri safety, indicated in local mri safety protocol

Keywords: postoperative cognitive dysfunction cognitive decline valve surgery cardiac surgery diffusion tensor imaging brain morphometry 1h-magnetic resonance spectroscopy
the effect of inspiratory muscle training on pediatric cancer patient

Conditions: Pediatric Cancer; Inspiratory Muscle Training

Summary: the aim of this study is to examine the effects of inspiratory muscle training on respiratory functions, functional capacity, fatigue and quality of life in pediatric cancer patients who have recently completed treatment. a total of 27 patients were included in the study. the patients were divided into two groups as training and control groups. after the initial evaluation of all patients, they were included in an 8-week inspiratory muscle training program. the final evaluation was made at the end of 8 weeks. according to the final evaluations, it was found that there was a statistical increase in favor of the training group on maximal inspiratory pressure, 6 minute walking test, quality of life and fatigue.

the aim of this study is to investigate the effects of inspiratory muscle training on respiratory functions, functional capacity, fatigue and quality of life in pediatric cancer patients. a total of 27 patients, 13 in the training group and 14 in the control group, who received and completed cancer treatment at the memorial şişli hospital pediatric oncology and hematology department and who met the inclusion criteria were included in the study. the age, gender, diagnosis, height and weight of the patients included in the study were recorded. evaluations were made regarding respiratory functions, respiratory muscle strength, functional capacity, fatigue and quality of life in the patients before and after inspiratory muscle training. in the study, the initial and post-training values of the fvc, % fvc, fev1, % fev1, fev1/fvc, pef and % pef in the respiratory function test of the patients in the training and control groups were compared. the mip and mep values of the patients in the training and control groups were compared with the initial and post-test values of spo2, heart rate and walking distance calculated after 6mwt. fatigue values of patients in the education and control groups before and after inspiratory muscle training were compared. physical, emotional, social and school-related baseline values obtained after the pediatric quality of life test in the education and control groups were compared.

Eligibility criteria:
inclusion criteria: * being between 8 and 18 years old * having been diagnosed with cancer and having completed treatment * having passed at least 30 and at most 120 days after completion of treatment. exclusion criteria: * having chronic lung disease, * having a history of hospitalization due to infection in the last month, * having a history of surgical intervention due to cancer, * having insufficient cognitive and cognitive functions, * having an orthopedic problem affecting mobility or a history of musculoskeletal surgical intervention, * having cancer relapse during the 8-week training program, * having received additional chemotherapy for any reason despite having completed treatment,

Keywords: pediatric cancer inspiratory muscle training respiratory function muscle strength
dose-finding of lenalidomide as maintenance in multiple myeloma

Conditions: Multiple Myeloma

Summary: this study is a phase i (non-randomized) study evaluating three dose-levels of lenalidomide in patients after allogeneic stem cell transplantation, accomplished in two institutions (university medical center hamburg-eppendorf/ university medical center heidelberg).


Eligibility criteria:
inclusion criteria: * understand and voluntarily sign informed consent form * age \> 18 years at the time of signing the informed consent form * able to adhere to the study visit schedule and other protocol requirements * multiple myeloma patients who received allogeneic stem cell transplantation (100 to 180 days ago) * no active acute gvhd (grade ii - iv) * no active infectious complications * ecog performance status of \< 2 at study entry * laboratory test results within these ranges: * absolute wbc count \> 3.0 x 10\^9/l * platelet count \> 80 x 10\^9/l * serum creatinine \< 1.5 mg/dl * total bilirubin \< 1,5 mg/dl * ast (sgot) and alt (sgpt) \< 3 x uln * females of childbearing potential must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse for at least 28 days before starting study drug, while participating in the study and at least 28 days after discontinuation from the study. * male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days after discontinuation of study drug * disease free of prior malignancies for \> 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast exclusion criteria: * any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form * pregnant or breast feeding females * use of any other experimental drug or therapy within 28 days of baseline * known hypersensitivity to thalidomide * concurrent use of other anti-cancer agents or treatments * known positive for hiv of infectious hepatitis, type a, b, or c

Keywords: multiple myeloma stem cell transplantation revlimid lenalidomide
safety study of cell therapy to treat chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease; Pulmonary Emphysema

Summary: the purpose of this study is to determine whether the cell therapy with bone marrow mononuclear cells is safe in the treatment of chronic obstructive pulmonary disease, specifically the pulmonary emphysema.

the main feature of the pulmonary emphysema, included in range of the chronic obstructive pulmonary disease (copd), is the airflow obstruction resulting from the destruction of the alveolar walls distal to the terminal bronchiole, without significant pulmonary fibrosis. the existing clinical approaches has contributed to the enlargement and amelioration of the emphysema patients life quality, although no effective or curative treatment has been achieved. the surgical treatment, on the other hand, involves complex procedures and, in the specific case of lung transplantation, a lack of donors. considering these aspects, several experimental models have been proposed aiming to increase knowledge about the pathophysiological processes and enable new clinical approaches to the pulmonary emphysema. the cell therapy, briefly described as the use of cells in disease treatment, presents itself as a promising therapeutic approach with great potential applicability in degenerative pulmonary diseases. in this way, it is intended in this project, the proposition of a protocol to evaluate the safety of cell therapy with pool of mononuclear cells from bone marrow in patients with clinical and laboratory diagnosis of pulmonary emphysema in advanced stage (stage iv dyspnea).

Eligibility criteria:
inclusion criteria: * diagnosis of severe chronic obstructive pulmonary disease * ineffective clinical treatment * limited life expectancy * limitations in daily physical activity * possibility of pulmonary rehabilitation physiotherapy * acceptable nutritional status * acceptable cardiac function * at least six months smoking cessation * family support * modified medical research council dyspnea scale stage \> 3 exclusion criteria: * pulmonary or extra-pulmonary infection * severe coronary disease and/or ventricular dysfunction * significant kidney or liver disease * immunosuppressive disease * active smoker * cancer * psychosocial problems * established medical protocol * family rejection * pregnancy

Keywords: chronic obstructive pulmonary disease emphysema cell therapy bone marrow mononuclear cells stem cells
non invasive ventilation during physical training in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: patients with cystic fibrosis older than 18 years will performance a bruce test with non invasive ventilation (once) after 30 minutes they perform the same test with oxygen supplementation. measurements: transcutaneous level off carbon dioxide, saturation, puls and dyspnea scale.

measurements before and after the test: transcutaneous level off carbon dioxide, saturation, respiratory rate, dyspnea scale.

Eligibility criteria:
inclusion criteria: * subjects with cystic fibrosis at stockholm cystic fibrosis center * \> 18 years of age * forced expiratory volume in one second (fev1) between 20 and 69% of predicted value * developed alveolar hypoventilation at the physical performance test * use oxygen supplementation during aerobic training exclusion criteria: * symptomatic upper airway infection characterized by fever less than 1 month before entering the study * cognitive dysfunction * cardio-respiratory instability * infection with burkholderia cepacia complex * gastroesophageal reflux * history of pneumothorax * massive hemoptysis.
pharmacokinetics of antibiotics in critically ill patients receiving cvvhf

Conditions: Sepsis; Acute Kidney Injury

Summary: the mortality in patients with sepsis and severe acute kidney injury requiring continuous renal replacement therapy (crrt) remains high. antibiotic therapy is a key treatment of these patients and in recent years new antibiotics have been licensed. however, data is lacking to determine the optimal dosing regimens of these antibiotics for high (australia and other countries) and low intensity (japan) of crrt. aim to establish the appropriate dosing regimens of newly available antibiotics during crrt can applied globally.


Eligibility criteria:
inclusion criteria: * adult (age ≥18 years or older) * sepsis (sepsis-3 criteria) * acute kidney injury requiring crrt (kdigo criteria) * eligible for intensive care without restrictions or limitations exclusion criteria: * chronic renal failure * obvious or suspected pregnancy * intracranial bleeding
a clinical study of cd19 targeted car-t for patients with cd19+ lymphoma and leukemia

Conditions: B Cell Leukemia; B Cell Lymphoma

Summary: immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. the newly designed cd19 targeted icar19 t cells can specifically kill cd19+ tumor cells. icar19 cart used the second generation of cart designation. in this study, the participants will receive several doses of autologous icar19 t cells and the investigators will determine the safety and therapeutic effects of these cells.


Eligibility criteria:
inclusion criteria: cd19 positive leukemia and lymphoma，relapsed and/or refractory： * survival\>12 weeks; * fev1, fvc and dlco ≥50% of expected corrected for hemoglobin; * lvef≥50%; * creatinine\<2.5mg/dl; * bilirubin\<2.5mg/dl; * alt (alanine aminotransferase)/ast (aspartate aminotransferase)\<3 x normal; * at least 7 days after last chemotherapy; * provide with informed consent. exclusion criteria: * active clinically significant cns dysfunction * pregnant or breast-feeding women. * uncontrolled active infection including hepatitis b or c. * hiv positive. * use of systemic steroids within 72 hours. * allogeneic lymphocyte treatments within recent 6 months. * any uncontrolled active medical disorder.
sb208 for the treatment of tinea pedis

Conditions: Tinea Pedis

Summary: this is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in non immunocompromised adult subjects with interdigital tinea pedis.

a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in approximately 170 non immunocompromised adult subjects with interdigital tinea pedis. subjects will apply the investigational product (ip) (sb208 or vehicle gel) to the interdigital areas and all affected and immediate surrounding areas of one or both feet once daily for 2 weeks, followed by a 4-week post-treatment observation period.

Eligibility criteria:
inclusion criteria: * otherwise healthy male and female subjects with clinical diagnosis of interdigital t. pedis * t.pedis provisionally confirmed at baseline by a positive koh wet mount for segmented fungal hyphae on skin scraping from the target site exclusion criteria: * women who are pregnant or nursing or planning on becoming pregnant * subjects with onychomycosis or moccasin-type t. pedis * subjects using topical or systemic anti-fungal agents
relation between dose and time to reinjection of botulinum toxin-a in patient with poststroke spasticity from a real-world healthcare insurance database.

Conditions: Post Stroke Spasticity

Summary: determining the mean/median time between botulinum toxin-a injection within the treatment of patients with spasticity after stroke in relation to the botulinum toxin dose from a healthcare insurance database in the netherlands.


Eligibility criteria:
inclusion criteria: * a patient will be included if he has a diagnosis stroke within the rehabilitation setting and has received at least two injections of botulinum toxin-a: dysport or botox exclusion criteria: * a patient will be excluded if he has been only treated with xeomin
[18f]fluoroestradiol-pet/ct companion imaging study to the foresee trial

Conditions: Estrogen Receptor Positive Breast Cancer

Summary: this protocol is a companion imaging study that will add fes-pet/ct imaging to the foresee trial at hci. this study will establish the feasibility of using fes-pet/ct imaging to guide therapeutic decision making for functional precision oncology trials. the unique ability of fes-pet/ct to show absence of functional estrogen receptors throughout the entire body may improve confidence among research oncologists that an er+ metastatic breast cancer patient is truly refractory to hormonal therapies which is a critical determination in the study design of the foresee trial.


Eligibility criteria:
inclusion criteria: * adults aged 18 years or greater. * all patients or legal guardians are willing and able to sign written informed consent and hipaa authorization in accordance with local and institutional guidelines. * enrolled on the foresee trial. * biopsy proven estrogen receptor positive breast cancer. * patient deemed refractory to all combinations of hormonal therapies by foresee trial investigators. exclusion criteria: * patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals. patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator's discretion. * patients who require monitored anesthesia for pet/ct scanning. * patients who are too claustrophobic to undergo pet/ct scanning. * patients who are pregnant or currently breast feeding. * any patient that is medically unstable defined as a patient requiring inpatient hospitalization or needing evaluation at an acute care or urgent care facility at the time of imaging.
dose finding study with cyt003-qbg10 in patients with house dust mite allergy

Conditions: Rhinoconjunctivitis; Allergies

Summary: the purpose of the study is to test whether vaccinations with cyt003-qbg10 can improve allergy symptoms in patients with house dust mite allergy. the active treatment will be compared against placebo.


Eligibility criteria:
inclusion criteria: * perennial allergic rhinoconjunctivitis due to clinically relevant allergy towards house dust mite allergens * further criteria as defined in the study protocol exclusion criteria: * clinically manifested seasonal allergy/-ies which is/are expected to interfere with the patient's study treatment schedule and/or assessments * clinically relevant perennial allergy/-ies other than house dust mites allergy * contraindication to any study test or procedure * further criteria as defined in the study protocol

Keywords: rhinoconjunctivitis due to house dust mite allergy
assessing medical trial experiences of hairy cell leukemia patients

Conditions: Hairy Cell Leukemia

Summary: the percentages of participants in clinical studies haven't always been perfectly representative of a particular group. this research examines the variables that affect a patient's choice to enroll in, discontinue participation in, or resume participation in a clinical trial for hairy cell leukemia. it will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of hairy cell leukemia studies.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old * ability to understand and the willingness to sign a written informed consent document. * willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. exclusion criteria: * is pregnant, breastfeeding or expecting to conceive within the projected duration of the study * any mental or medical condition that prevents the patient from giving informed consent or participating in the trial * patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.

Keywords: hairy cell leukemia
electroencephalogram (eeg) triggered functional magnetic resonance imaging (fmri) in epilepsy patients

Conditions: Epilepsy

Summary: a prospective exploratory study in patients with drug resistant epilepsy with a target comparison of long term outcome. neuroscan software modules and a maglink will be used to acquire eeg in combination with mri/fmri data. the maglink system is used for obtaining integrated eeg and event related potential (erp) recordings while the subject is inside the mri machine, without compromising the raw eeg data.


Eligibility criteria:
inclusion criteria: 1. refractory epilepsy cases, referred by the service of neurology. these are cases whose pathophysiology is resistant to treatment, including change in medication and or added medication. 2. patients will be included if they agree to sign an institutional review board approved written consent. exclusion criteria: 1. patients with overt symptoms or signs of anxiety than cannot cooperate during the recording inside the scanner, unless consent is given for the procedure to be performed with sedation by the anesthesia department. 2. patients who meet the regular exclusion criteria for magnetic resonance imaging (mri) studies per the prescreening form reviewed with all patients prior to exams

Keywords: eeg triggered fmri epilepsy intractable